Journal article

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib

Michael Friedlander, Catherine Shannon, Jeffrey Goh, Clare Scott, Linda Mileshkin

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2018

Abstract

PURPOSE: Olaparib was originally formulated as 50 mg capsules with a recommended dose of 400 mg twice daily which requires patients to take 16 capsules a day. More recently, a tablet formulation with equivalent efficacy has become available and reduces the pill burden for patients to two tablets twice daily which is more convenient for patients. However, it is important to understand the key differences between the olaparib capsule and tablet formulations as they are not bioequivalent, and the doses are not interchangeable. Educating patients when transitioning from capsules to tablets is critical to avoid dosing errors and maintain both safety and efficacy of olaparib maintenance therapy. M..

View full abstract